Ars Pharmaceuticals Insider Sold Shares Worth $657,625, According to a Recent SEC Filing
ARS Pharmaceuticals Files for Approval of Neffy in China, Japan and Australia
Express News | ARS Pharmaceuticals Files For Approval Of Neffy In China, Japan And Australia
Express News | Form 144 | ARS Pharmaceuticals(SPRY.US) Officer Proposes to Sell 4.02 Million in Common Stocks
ARS Pharmaceuticals | 10-Q/A: Quarterly report (Amendment)
Insider Sale: Director at $SPRY (SPRY) Sells 14,772 Shares
ARS Pharmaceuticals Announces That It Will Be Launching The NeffyinSchools Program In January 2025; The Program Will Provide Eligible Public And Private K-12 Schools In The U.S. The Opportunity To Receive Two Cartons Of Neffy 2mg For Use In Emergency...
ARS Pharmaceuticals Announces Planned Launch of NeffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
Trade Alert: Chief Business Officer & Secretary Of ARS Pharmaceuticals Justin Chakma Has Sold Stock
Form 144 | ARS Pharmaceuticals(SPRY.US) Officer Proposes to Sell 4.09 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 15, $ARS Pharmaceuticals(SPRY.US)$ Officer Chakma Justin intends to sell 236.38K shares of its common stock on Nov 15, with a total market value of approximately $4.09
Express News | Neurelis Enters $208 Million Agreement to Monetize Intravail Royalties
ARS Pharmaceuticals Insider Sold Shares Worth $10,143,706, According to a Recent SEC Filing
Express News | ARS Pharmaceuticals Inc : Leerink Partners Raises Target Price to $26 From $25
ARS Pharmaceuticals' Strong Q3 2024 Highlights
ARS Pharmaceuticals(SPRY.US) 10% Shareholder Sells US$10.14 Million in Common Stock
ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript Summary
Express News | ARS Pharmaceuticals Shares Are Higher Lower After the Company Reported Better-than-expected Q3 Sales Results
ARS Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
ARS Pharmaceuticals | 8-K: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
ARS Pharmaceuticals' Q3 Net Loss Widens